Articles with public access mandates - Eduardo R. ZimmerLearn more
Not available anywhere: 7
Astrocyte biomarkers in Alzheimer’s disease
SF Carter, K Herholz, P Rosa-Neto, L Pellerin, A Nordberg, ER Zimmer
Trends in molecular medicine 25 (2), 77-95, 2019
Mandates: Swedish Research Council, Agence Nationale de la Recherche
Reduced brain insulin-like growth factor I function during aging
AP Muller, AM Fernandez, C Haas, E Zimmer, LV Portela, I Torres-Aleman
Molecular and Cellular Neuroscience 49 (1), 9-12, 2012
Mandates: Government of Spain
Use of amyloid PET across the spectrum of Alzheimer’s disease: clinical utility and associated ethical issues
A Leuzy, ER Zimmer, K Heurling, P Rosa-Neto, S Gauthier
Amyloid 21 (3), 143-148, 2014
Mandates: Canadian Institutes of Health Research, Fonds de recherche du Québec - Santé
The GABAergic system in Alzheimer’s disease: a systematic review with meta-analysis
G Carello-Collar, B Bellaver, PCL Ferreira, JP Ferrari-Souza, VG Ramos, ...
Molecular Psychiatry 28 (12), 5025-5036, 2023
Mandates: Fonds de recherche du Québec - Santé
Nonamyloid PET biomarkers and Alzheimer's disease: current and future perspectives
LP Schilling, A Leuzy, ER Zimmer, S Gauthier, P Rosa-Neto
Future Neurology 9 (6), 597-613, 2014
Mandates: Canadian Institutes of Health Research, Fonds de recherche du Québec - Santé
The glutamatergic system in alzheimer’s disease: A systematic review with meta-analysis
C Soares, LU Da Ros, LS Machado, A Rocha, G Lazzarotto, ...
Molecular Psychiatry, 1-13, 2024
Mandates: Fonds de recherche du Québec - Santé
Clinical correlates of the PET-based Braak staging framework in Alzheimer’s disease
AC Macedo, D Durço, C Tissot, J Therriault, AO Vilela de Faria, E Aumont, ...
The Journal of Prevention of Alzheimer's Disease 11 (2), 414-421, 2024
Mandates: Fonds de recherche du Québec - Santé
Available somewhere: 72
Reactive astrocyte nomenclature, definitions, and future directions
C Escartin, E Galea, A Lakatos, JP O’Callaghan, GC Petzold, ...
Nature neuroscience 24 (3), 312-325, 2021
Mandates: Swiss National Science Foundation, US National Institutes of Health, German …
Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum
AL Benedet, M Milà-Alomà, A Vrillon, NJ Ashton, TA Pascoal, F Lussier, ...
JAMA neurology 78 (12), 1471-1483, 2021
Mandates: US National Institutes of Health, Canadian Institutes of Health Research …
[18F]FDG PET signal is driven by astroglial glutamate transport
ER Zimmer, MJ Parent, DG Souza, A Leuzy, C Lecrux, HI Kim, S Gauthier, ...
Nature neuroscience 20 (3), 393-395, 2017
Mandates: Canadian Institutes of Health Research, Fonds de recherche du Québec - Santé
Tracking neuroinflammation in Alzheimer’s disease: the role of positron emission tomography imaging
ER Zimmer, A Leuzy, AL Benedet, J Breitner, S Gauthier, P Rosa-Neto
Journal of neuroinflammation 11, 1-12, 2014
Mandates: Canadian Institutes of Health Research, Fonds de recherche du Québec - Santé
Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease
B Bellaver, G Povala, PCL Ferreira, JP Ferrari-Souza, DT Leffa, ...
Nature medicine 29 (7), 1775-1781, 2023
Mandates: US National Institutes of Health, Canadian Institutes of Health Research …
Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
NJ Ashton, AL Benedet, TA Pascoal, TK Karikari, J Lantero-Rodriguez, ...
EBioMedicine 76, 2022
Mandates: Canadian Institutes of Health Research, Fonds de recherche du Québec - Santé …
Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography
J Therriault, M Vermeiren, S Servaes, C Tissot, NJ Ashton, AL Benedet, ...
JAMA neurology 80 (2), 188-199, 2023
Mandates: US National Institutes of Health, Canadian Institutes of Health Research …
Astrocyte biomarkers in Alzheimer disease: a systematic review and meta-analysis
B Bellaver, JP Ferrari-Souza, L Uglione da Ros, SF Carter, ...
Neurology 96 (24), e2944-e2955, 2021
Mandates: Canadian Institutes of Health Research, Fonds de recherche du Québec - Santé
Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer’s disease
AL Benedet, A Leuzy, TA Pascoal, NJ Ashton, S Mathotaarachchi, ...
Brain 143 (12), 3793-3804, 2020
Mandates: US Department of Defense, US National Institutes of Health, Canadian …
Synaptic vesicle protein 2A as a potential biomarker in synaptopathies
K Heurling, NJ Ashton, A Leuzy, ER Zimmer, K Blennow, H Zetterberg, ...
Molecular and Cellular Neuroscience 97, 34-42, 2019
Mandates: Knut and Alice Wallenberg Foundation, Swedish Research Council, UK Medical …
Consequences of metabolic disruption in Alzheimer's disease pathology
JC Ryu, ER Zimmer, P Rosa-Neto, SO Yoon
Neurotherapeutics 16 (3), 600-610, 2019
Mandates: US National Institutes of Health
Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease
JP Ferrari-Souza, PCL Ferreira, B Bellaver, C Tissot, YT Wang, DT Leffa, ...
Molecular psychiatry 27 (11), 4781-4789, 2022
Mandates: US National Institutes of Health, Canadian Institutes of Health Research …
Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid‐positive individuals
AL Benedet, NJ Ashton, TA Pascoal, A Leuzy, S Mathotaarachchi, ...
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 11 (1 …, 2019
Mandates: US Department of Defense, US National Institutes of Health, Canadian …
Publication and funding information is determined automatically by a computer program